Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
Authors
Keywords
Imipenem, Relebactam, Carbapenem-nonsusceptible, Enterobacteriaceae, in vivo, Caenorhabditis elegans
Journal
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-24
DOI
10.1016/j.jmii.2021.02.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae
- (2020) Tsung-Ying Yang et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
- (2019) Ilias Karaiskos et al. Expert Opinion on Drug Metabolism & Toxicology
- Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012-2015
- (2019) Ya-Ting Chang et al. Infection and Drug Resistance
- Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance
- (2019) Jessica Carpenter et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
- (2019) Patrice Nordmann et al. CLINICAL INFECTIOUS DISEASES
- in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli
- (2018) Suzannah M. Schmidt-Malan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem/Cilastatin in Murine Infection Models
- (2018) Mary Ann Powles et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem Nonsusceptible Klebsiella pneumoniae in Taiwan: Dissemination and Increasing Resistance of Carbapenemase Producers During 2012–2015
- (2018) Sheng-Kang Chiu et al. Scientific Reports
- Activity of Imipenem-Relebactam against Gram-Negative Bacilli from Global ICU and Non-ICU Wards — SMART 2015-2016
- (2018) Sibylle H. Lob et al. Journal of Global Antimicrobial Resistance
- β-lactam/β-lactamase inhibitor combinations: an update
- (2018) Kamaleddin H. M. E. Tehrani et al. MedChemComm
- In vitro activity of ceftazidime–avibactam, ceftolozane–tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
- (2018) Shio-Shin Jean et al. Infection and Drug Resistance
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
- (2016) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of a Manufacturing Route to Avibactam, a β-Lactamase Inhibitor
- (2016) Matthew Ball et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
- (2014) Timothy A. Blizzard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases
- (2014) A. Jain et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- First Report ofblaIMP-8in Raoultella planticola
- (2013) Sung-Pin Tseng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started